Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ERAS vs ANL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ERAS Captures Overall Composite Edge (37.5 SELL vs 48.3 HOLD), While ANL Leads 4–1 on Growth & Valuation Pillars

ERAS Overall Winner 6-Pillar Tally: ERAS 1 – 4 ANL (1 Tie) Matrix Metrics: ERAS 4 – 4 ANL

As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (37.5/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while ANL wins 4–1 across the 6-pillar growth and valuation breakdown. ERAS trades at $14.95 (N/M Forward P/E, 0.0% operating margin) versus ANL at $9.97 (N/M Forward P/E, -123.5% operating margin).

  • Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY).
  • Technical & Structure Timing Caution: ERAS is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ERAS vs ANL
ERAS NASDAQ Head-to-Head Winner
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$14.95
-4.57% 1D
Market Cap $5.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.31β · 81% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 20.0 Fund 47.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -7.2%) with fading momentum, RSI 49
RSI-14: 49.4 · SMA20: $14.89 · SMA50: $14.93
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92

6-Pillar Scorecard Institutional Category Breakdown (ERAS 1 – 4 ANL)

Columns: Metric · ERAS · ANL
1. Valuation Multiples ANL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 37.5x
2. Growth & Scale ANL
Revenue Growth (YoY) +0.0% +178.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $18M
Market Cap $5.5B $677.5M
3. Profitability & Quality ERAS
Gross Margin N/A 100.0%
Operating Margin 0.0% -123.5%
Net Profit Margin 0.0% -124.8%
Return on Equity (ROE) -48.7% -20.2%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$252M -$22M EBITDA
Cash Flow Margin N/A -119.9% EBITDA Mgn
Net Cash / Leverage $2.2M Net Debt (0.12x D/E) $3.34 Book/Sh · -20.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 89.2% (13th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ERAS (4) vs ANL (4)
Institutional Metric ERAS ANL Criterion Row Edge
Market Capitalization
Scale
$5.5B $677.5M Larger Scale ERAS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +178.1% Higher Growth ANL
Operating Margin (TTM)
Profitability
0.0% -123.5% Higher Margin ERAS
Net Profit Margin
Profitability
0.0% -124.8% Higher Margin ERAS
Return on Equity (ROE)
Capital Efficiency
-48.7% -20.2% Higher ROE ANL
52-Week Range Position
Momentum
57% ($2–$24) 56% ($1–$17) Stronger Trend ERAS
Beta / 30D Volatility
Risk Regime
2.31β · 81% Vol 2.61β · 79% Vol Lower Realized Risk ANL
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 48.3 / 100 (HOLD) Higher Composite ANL
Trailing 12M Revenue (USD)
Operating Scale
N/A $18M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 37.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$252M ($2.2M Net Debt (0.12x D/E)) -$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ERAS +21.22 pp
ERAS: +11.61% · ANL: -9.61%
3M Horizon ERAS +12.16 pp
ERAS: -17.43% · ANL: -29.59%
6M Horizon ERAS +59.65 pp
ERAS: +45.52% · ANL: -14.13%
1Y Horizon ANL +71.87 pp
ERAS: +488.39% · ANL: +560.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ERAS vs ANL. Trailing 12-month operating profitability (ERAS 0.0% vs ANL -123.5%) and valuation multiples (ERAS N/M vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ERAS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-48.7% · N/M
ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ERAS BREAKDOWN
87d in phase · OBV NEUTRAL
Current IV 89.2%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ERAS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ERAS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ERAS vs ANL Key Questions & Quantitative Answers

As of Nov 16, 2026, Erasca, Inc. (ERAS) captures the overall head-to-head institutional edge over ANL (ANL) on higher Unified Composite conviction (37.5/100 SELL vs. 48.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while ANL wins 4–1 across the 6-pillar growth and valuation breakdown. ERAS trades at $14.95 (N/M Forward P/E, 0.0% operating margin) versus ANL at $9.97 (N/M Forward P/E, -123.5% operating margin). Composite vs. Pillar Nuance: While ANL currently prints a higher short-term Unified Composite Score (48.3/100 HOLD vs. ERAS 37.5/100 SELL), ERAS captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -123.5% operating margin) and revenue trajectory (+0.0% vs. +178.1% YoY). Technical & Structure Timing Caution: ERAS is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.4); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: ERAS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANL at +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin). On trailing 12-month operating scale, ERAS generates N/A in USD-normalized revenue versus $18M for ANL. In operating R&D and SG&A reinvestment, ERAS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANL.

ANL screens cheaper on headline valuation multiples. ERAS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ERAS (-48.7% ROE) versus ANL (-20.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ERAS carries 89.2% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 81% Vol realized risk). By comparison, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.